Pharmaceutical programs and social policy development: comparing Canada, Australia and the UK

Canada is the only OECD country that provides broad public health benefits but lacks a universal, nation-wide system for funding prescription drugs. This puzzle cannot be explained by the literature on national health insurance, which suggests that the tendency to consider all health services as a s...

Full description

Bibliographic Details
Main Author: Boothe, Katherine
Language:English
Published: University of British Columbia 2010
Online Access:http://hdl.handle.net/2429/26266
id ndltd-LACETR-oai-collectionscanada.gc.ca-BVAU.2429-26266
record_format oai_dc
spelling ndltd-LACETR-oai-collectionscanada.gc.ca-BVAU.2429-262662014-03-26T03:37:07Z Pharmaceutical programs and social policy development: comparing Canada, Australia and the UK Boothe, Katherine Canada is the only OECD country that provides broad public health benefits but lacks a universal, nation-wide system for funding prescription drugs. This puzzle cannot be explained by the literature on national health insurance, which suggests that the tendency to consider all health services as a single policy has missed an important source of cross-national variation. How can we explain the lack of a major pharmaceutical program in Canada, in light of the country’s own extensive health system and the experience of almost all other welfare states? More generally, why do some countries adopt universal, comprehensive pharmaceutical programs, while others do not? To answer these questions, the study compares Canada to the UK and Australia using a process-tracing approach, and finds that the range of services in a country’s public health system is determined by the earliest decisions about how to approach policy development. Where institutional, ideological and electoral conditions allowed for large-scale change and all services were introduced simultaneously, countries tended to maintain the full scope of services. But where institutional barriers, ideological dissensus and low issue salience made radical change difficult, health programs were introduced incrementally, and policy development tended to stall after the first priority. Although incrementalism was initially less politically risky, it was also inherently limiting. Barriers to the introduction of services increased over time, and services that were initially lower priorities (such as pharmaceuticals in Canada) were pushed off the public agenda. In investigating this phenomenon, I provide specific mechanisms by which a more limited “path” of policy development becomes “dependent,” and argue that we must consider not only the role of ideas in policy making, but also the role of ideas over time. The study also investigates the implications of the approach to policy development for subsequent policy outcomes. It finds that factors that support the simultaneous adoption of a full range of health services also make it more difficult to retrench these services later on. 2010-07-09T17:53:18Z 2010-07-09T17:53:18Z 2010 2010-07-09T17:53:18Z 2010-11 Electronic Thesis or Dissertation http://hdl.handle.net/2429/26266 eng University of British Columbia
collection NDLTD
language English
sources NDLTD
description Canada is the only OECD country that provides broad public health benefits but lacks a universal, nation-wide system for funding prescription drugs. This puzzle cannot be explained by the literature on national health insurance, which suggests that the tendency to consider all health services as a single policy has missed an important source of cross-national variation. How can we explain the lack of a major pharmaceutical program in Canada, in light of the country’s own extensive health system and the experience of almost all other welfare states? More generally, why do some countries adopt universal, comprehensive pharmaceutical programs, while others do not? To answer these questions, the study compares Canada to the UK and Australia using a process-tracing approach, and finds that the range of services in a country’s public health system is determined by the earliest decisions about how to approach policy development. Where institutional, ideological and electoral conditions allowed for large-scale change and all services were introduced simultaneously, countries tended to maintain the full scope of services. But where institutional barriers, ideological dissensus and low issue salience made radical change difficult, health programs were introduced incrementally, and policy development tended to stall after the first priority. Although incrementalism was initially less politically risky, it was also inherently limiting. Barriers to the introduction of services increased over time, and services that were initially lower priorities (such as pharmaceuticals in Canada) were pushed off the public agenda. In investigating this phenomenon, I provide specific mechanisms by which a more limited “path” of policy development becomes “dependent,” and argue that we must consider not only the role of ideas in policy making, but also the role of ideas over time. The study also investigates the implications of the approach to policy development for subsequent policy outcomes. It finds that factors that support the simultaneous adoption of a full range of health services also make it more difficult to retrench these services later on.
author Boothe, Katherine
spellingShingle Boothe, Katherine
Pharmaceutical programs and social policy development: comparing Canada, Australia and the UK
author_facet Boothe, Katherine
author_sort Boothe, Katherine
title Pharmaceutical programs and social policy development: comparing Canada, Australia and the UK
title_short Pharmaceutical programs and social policy development: comparing Canada, Australia and the UK
title_full Pharmaceutical programs and social policy development: comparing Canada, Australia and the UK
title_fullStr Pharmaceutical programs and social policy development: comparing Canada, Australia and the UK
title_full_unstemmed Pharmaceutical programs and social policy development: comparing Canada, Australia and the UK
title_sort pharmaceutical programs and social policy development: comparing canada, australia and the uk
publisher University of British Columbia
publishDate 2010
url http://hdl.handle.net/2429/26266
work_keys_str_mv AT boothekatherine pharmaceuticalprogramsandsocialpolicydevelopmentcomparingcanadaaustraliaandtheuk
_version_ 1716655632261578752